A Comparison with Standard Chemotherapy and Best Supportive Care: Cost-Effectiveness of Vinorelbine Alone or Vinorelbine Plus Cisplatin for Stage IV NSCLC

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 4, 1998, Pages 18-25

  Evans, William K ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; NAVELBINE; ONDANSETRON; VINBLASTINE;

ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; QUALITY OF LIFE; SIDE EFFECT;

EID: 0031979928     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Le Chevalier T, Brisgand D, Douillard JY, et al: A randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell carcinoma Results of a European multicenter trial including 612 patients J Clin Oncol 12:360-367, 1994.
2. Goss GD, Logan DL, Newman TE, et al: Use of vinorelbine in non-small cell lung cancer. Cancer Prevention and Control 1.28-38, 1997.
3. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicentre randomized trial. J Clin Oncol 6:633-641, 1988.
4. Wolfson MC POHEM - a framework for understanding and modelling the health of human populations. Presented at Bureau of Census 1992 Annual Research Conference. Arlington, Virginia. Proc Ann Res Conf, pp 261-282, 1992.
5. Evans WK, Will BP, Berthelot J-M, et al: Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 72:1270-1277, 1995
6. Evans WK, Will BP, Berthelot J-M, et al: Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol 5:408-419, 1995
7. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the cost of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 8:1301-1309, 1990.
8. Wodinsky HB, DeAngelis C, Rusthoven JJ, et al: Re-evaluating the cost of outpatient cancer chemotherapy. Can Med Assoc J 137:903-906, 1987
9. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 3:176-183, 1985.
10. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4.14-22, 1996.
11. Grilli R, Oxman, AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993.
12. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in non-small-cell lung cancer: A meta-analysis using updated individual patient data from 52 randomized clinical trials. Lancet 342:19-21 1993.
13. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer. A meta-analysis using updated individual patient data from 52 clinic trials. Br Med J 311:899-909, 1995.
14. Cullen MH, Woodroffe CM, Billingham AD, et al. Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): Results of a randomized trial in patients with extensive disease (abstract 11). Lung Cancer 18(suppl 1):4, 1997.
15. Billingham LJ, Cullen MH, Woods J et al: Mitomycin, ifosfamide and cisplatin (MIC) in non-small-cell lung cancer (NSCLC). Results of a randomized trial evaluating palliation and quality of life (abstract 26). Lung Cancer 18(suppl 1):9, 1997.
16. Raby B, Pater J, MacKillop WJ Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13:1904-1911, 1995.
17. Moore R, Mao Y, Zhang J, et al: Economic burden of illness in Canada 1993. Catalogue no. H 21-136/1993 E. Public Works and Government Services. Canada, 1997.
18. Smith TJ, Hillner BE, Neighbours DM, et al: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 13:2166-2173, 1995.
19. Laupacis A, Feeney D, Detsky AS, et al: How attractive does new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481, 1992.
20. Shulman KA, Lynn LA, Glick HA, et al: Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV). Ann Intern Med 114:798-802, 1991.
21. Tangs TO, Adams ME, Pliskin JS, et al. 500 life-saving interventions and their cost-effectiveness. Risk Analysis 15:369-390, 1995.
22. Evans WK, Le Chevalier T: The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer 32: 2249-2255, 1996.
23. Earle C, Evans WK, Berthelot J-M, et al: Comparison of the costs, toxicities and inconvenience of the different chemotherapy regimens for advanced non-small-cell lung cancer (abstract 90). Lung Cancer 18(suppl 1):26, 1997.